Immunoreactive neuron-specific enolase, bombesin, and chromogranin as markers for neuroendocrine lung tumors
References (25)
- et al.
Keratin proteins and carcinoembryonic antigen in lung carcinoma
Hum Pathol
(1983) - et al.
Neuron-specific enolase is produced by neuroendocrine tumours
Lancet
(1981) - et al.
Bombesin production by human small cell carcinoma of the lung
Regula Pept
(1982) Histological typing of lung tumours
- et al.
Immunologic characterization and ultrastructural correlations for 125 cases of B- and T-cell leukemias
Cancer
(1981) - et al.
Specific endocrine tissue marker defined by a monoclonal antibody
Science
(1983) Spectrum of lung cancer and ectopic hormones
Pathol Annu
(1978)The APUD cell concept and its implications in pathology
Pathol Annu
(1974)- et al.
Neuron-specific enolase is a molecular marker for peripheral and central neuroendocrine cells
Nature
(1978) - et al.
Serum neuronspecific enolase: a marker for disease extent and response to therapy for small-cell lung cancer
Lancet March
(1982)
Neuron specific enolase (NSE) immunostaining. A useful tool for the light microscopical detection of endocrine cell hyperplasia in rats exposed to asbestos
Histochemistry
Immunocytochemical localisation of neuron specific enolase in small cell carcinomas and carcinoid tumours of the lung
Histopathology
Cited by (129)
Clinicopathological and prognostic significance of thyroid transcription factor-1 expression in small cell lung cancer: A systemic review and meta-analysis
2019, Pathology Research and PracticeCitation Excerpt :Yao et al. found that TTF-1 expressed in 83% of small cell prostate carcinoma and Ordonez et al. reported that TTF-1 only expressed in 7% of cases [12,13]. So, TTF-1 is not an exclusively pulmonological biomarker, which is proved by the fact that non-pulmonary small cell carcinomas also express other neuroendocrine markers as well as SCLC, such as the neuro-specific enolase (NSE), CD56 and chromogranin A [33–37]. Therefore, the value of TTF-1 for diagnosis of SCLC remains questionable.
Immunohistochemical Validation of Spontaneously Arising Canine Osteosarcoma as a Model for Human Osteosarcoma
2017, Journal of Comparative PathologyCitation Excerpt :In addition to tumours of neural origin, NSE is expressed by numerous non-neural tumours (Mjones et al., 2017; Zhou et al., 2017b). In man, this tumour marker is frequently used to diagnose Ewing's sarcoma (Gao and Kahn, 2005) and is one of the panel of tumour markers used to diagnose neuroendocrine tumours (Said et al., 1985). We detected cytoplasmic expression of NSE in 56% of canine OSs.
Proteomic analysis of formalin-fixed, paraffin-embedded lung neuroendocrine tumor samples from hospital archives
2011, Journal of ProteomicsCitation Excerpt :Indeed, candidate biomarkers listed in Table 2, upon a wider validation, might considerably help to increase sensitivity and specificity in the differential diagnosis of TC and SCLC (and intermediate subtypes). Among them, CgA can be considered as a good internal control, being a well-known neuroendocrine marker generally more expressed in TCs than in SCLCs [48–51], whose differential abundance has been confirmed here also by IHC. Stathmin, also known as oncoprotein-18 (Op18), is a ubiquitous, highly conserved cytosolic protein which is primarily involved in regulation of microtubule dynamics, in relation to multisite phosphorylation of its serine residues [52].
Neuroendocrine Lesions of the Lung
2011, Practical Pulmonary Pathology E-Book: A Diagnostic Approach, Second EditionNeuroendocrine Lesions of the Lung
2011, Practical Pulmonary Pathology: A Diagnostic Approach A Volume in the Pattern Recognition SeriesImmunohistochemistry
2009, Modern Surgical Pathology
- *
Received from the Division of Anatomic Pathology and Pulmonary Medicine, Cedars-Sinai Medial Center, Los Angeles, California
- †
Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan